Usher Syndrome – Pipeline Review, H2 2016

Categories: Central Nervous System Drugs, Drugs by Therapeutic Area, Pharmaceuticals

Price: $2,000

Description

Usher Syndrome - Pipeline Review, H2 2016

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Usher Syndrome - Pipeline Review, H2 2016, provides an overview of the Usher Syndrome (Genetic Disorders) pipeline landscape.

Usher syndrome is an inherited condition characterized by hearing impairment and progressive vision loss. The major symptoms of Usher syndrome are hearing loss and an eye disorder called retinitis pigmentosa. Risk factors include retinal degeneration, prolonged, unprotected exposure to sunlight may accelerate vision loss. Treatment includes cochlear implants, hearing aids and Vitamin A supplementation.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Usher Syndrome - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Usher Syndrome (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Usher Syndrome (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Usher Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Discovery stages are 2 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Usher Syndrome (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Usher Syndrome (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Usher Syndrome (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Usher Syndrome (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Usher Syndrome (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Usher Syndrome (Genetic Disorders)

Reasons to Buy:

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Usher Syndrome (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Usher Syndrome (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Introduction

Usher Syndrome Overview

Therapeutics Development

Pipeline Products for Usher Syndrome - Overview

Pipeline Products for Usher Syndrome - Comparative Analysis

Usher Syndrome - Therapeutics under Development by Companies

Usher Syndrome - Therapeutics under Investigation by Universities/Institutes

Usher Syndrome - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Usher Syndrome - Products under Development by Companies

Usher Syndrome - Products under Investigation by Universities/Institutes

Usher Syndrome - Companies Involved in Therapeutics Development

Amgen Inc

Editas Medicine Inc

ProQR Therapeutics NV

Sanofi

Usher Syndrome - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

Gene Therapy for Usher Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate MYO7A for Usher Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NT-501 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

QRX-411 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAR-421869 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Usher Syndrome - Dormant Projects

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Usher Syndrome, H2 2016

Number of Products under Development for Usher Syndrome - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Investigation by Universities/Institutes, H2 2016

Usher Syndrome - Pipeline by Amgen Inc, H2 2016

Usher Syndrome - Pipeline by Editas Medicine Inc, H2 2016

Usher Syndrome - Pipeline by ProQR Therapeutics NV, H2 2016

Usher Syndrome - Pipeline by Sanofi, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Usher Syndrome - Dormant Projects, H2 2016

List of Figures:

Number of Products under Development for Usher Syndrome, H2 2016

Number of Products under Development for Usher Syndrome - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Targets, H2 2016

Number of Products by Stage and Targets, H2 2016

Number of Products by Mechanism of Actions, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2

Companies Mentioned

  • Amgen Inc
  • Editas Medicine Inc
  • ProQR Therapeutics NV
  • Sanofi